A recent study conducted by Charles River Associates, a leading global consulting firm, has quantified the savings consumers and the healthcare system receive from the over-the-counter (OTC) availability of the widely used cough suppressant dextromethorphan (DXM).
Government officials have tried to balance the positives of OTC access against the negatives of potential abuse. This paper aims to inform this discussion by quantifying various costs that would result if products with DXM were converted from OTC to Rx.
Our member companies generally support the recommendations found in the guidance but have concerns about the scope of hardness measurements and maximum break strength value.
CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive, and accommodating to innovation.
Substance Abuse Treatment, Prevention, and Policy recently published a case study authored by CHPA about the association’s efforts to curb teen abuse of OTC cough medicine containing dextromethorphan.
CHPA released the following statement today in support of a Delaware law prohibiting the sale of OTC medicines containing the cough suppressant dextromethorphan (DXM) to minors.
